Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Percent of patients completing the study treatment
研究概览
简要总结
Patients with GBM, who were deemed ineligible for any active protocols at our centre, received accelerated hypofractionation EBRT if 60Gy/20Fx using an IMRT technique with conventional dose of concomitant and adjuvant TMX as per the STUPP's TMZ schedule. Thirty five patients, 15 females and 20 males with a median age of 63 (range 31-78) were treated with a median KPS of 90 (range 50-100). Four patients had multicentric disease at presentation. Eight patients had biopsy only while the rest had a near total resection (n=14) and partial resection (n=13) with a median follow-up of 12.1 months, the median survival was 14.4 months.
详细描述
In this proposal, the total cumulative dose of TMZ is unchanged as compared to the doses used in the Stupp protocol. In this proposal, the dose of TMZ is the same, with the sole difference that TMZ will be given in a neo-adjuvant setting for two weeks and then continued at the same dose concurrently with the accelerated hypofractionated EBRT delivering 60Gy in 4 weeks. The adjuvant component of TMZ remains unchanged from current standard practice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 years or older
- •Histological confirmation of supratentorial GBM
- •KPS > 60
- •Neurological function 0 or 1
- •Adequate bone marrow as defined below:
- •absolute neutrophil count (ANC) > 1500 cells/mm3
- •platelets > 100,000 cells/mm3
- •hemoglobin > 10g/dl
- •Adequate renal function as defined below:
- •BUN < 25mg/dl within 14 days prior to study registration
- •creatinine of 63 to 103 umol/L within 14 days prior to study registration
- •Adequate hepatic function as defined below:
- •Bilirubin of 3 to 21 umol/L within 14 days prior to study registration
- •ALT & AST < 3xnormal range within 14 days prior to study registration
- •Neoadjuvant TMZ to start within 3 weeks of surgery/biopsy if no resection was deemed feasible
- •A diagnostic contrast-enhanced MRI or CT scan of the brain must be performed preoperatively and postoperatively.
- •History, physical and neurological examination within 14 days prior to study registration.
- •For females of child-bearing potential, negative pregnancy test within 72 hours prior to starting TMZ.
- •Able to sign an informed study-specific consent
排除标准
- •Margin of contrast-enhanced residual mass closer than 15mm from the optic chiasm or optic nerves.
- •Prior invasive malignancy, unless disease-free for >3years
- •Recurrent or multifocal GBM
- •Severe co-morbidities such as
- •unstable angina
- •transmural myocardial infarction within 6 months
- •COPD at the time of registration
- •Hepatic insufficiency
- •Bacterial or fungal infection requiring IV antibiotics at the time of registration
- •Acquired Immune Deficiency Syndrome (AIDS)
- •Major medical illnesses or psychiatric impairments
- •Pregnant women or lactating women
研究组 & 干预措施
Temozolomide, Accelerated Hypofractionated RT
Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
干预措施: Temozolomide and Accelerated Hypofractionation RT (Drug)
Temozolomide, Accelerated Hypofractionated RT
Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
干预措施: IMRT Technique (Radiation)
Temozolomide, Accelerated Hypofractionated RT
Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
干预措施: IMRT and accelerated hypofractionation technique (Radiation)
Temozolomide, Accelerated Hypofractionated RT
Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
干预措施: neo-adjuvant TMZ followed by accelerated hypofractionated EBRT (Radiation)
结局指标
主要结局
Percent of patients completing the study treatment
时间窗: At one year
To determine overall survival.
To assess toxicity of the regimen
时间窗: At one year
Toxicity will be assessed and graded according to CTCAE-V3
次要结局
未报告次要终点
研究者
George Shenouda
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre